UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

Working conditions and common mental disorders in physicians in Brazil

Occupational medicine (Oxford), 2013-04, Vol.63 (3), p.234-237

2013

Volltextzugriff (PDF)

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin

Diabetic medicine, 2011-01, Vol.28 (1), p.100-108

2011

Volltextzugriff (PDF)

Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia

Atherosclerosis, 1998-05, Vol.138 (1), p.217-225

1998

Volltextzugriff (PDF)

Indications for cholesterol-lowering medication: comparison of risk-assessment methods

The Lancet (British edition), 1999-01, Vol.353 (9149), p.278-281

1999

Volltextzugriff (PDF)

Methods for the prediction of coronary heart disease risk

Heart (British Cardiac Society), 2001-05, Vol.85 (5), p.489-490

2001

Volltextzugriff (PDF)

Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia

European journal of clinical nutrition, 1994-12, Vol.48 (12), p.859-865

1994

Volltextzugriff (PDF)

Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease

Atherosclerosis, 1993-01, Vol.98 (1), p.25-32

1993

Volltextzugriff (PDF)

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double‐blind placebo‐controlled trial of high‐ vs. low‐dose atorvastatin1

Diabetic medicine, 2011-01, Vol.28 (1), p.100-108

2011

Volltextzugriff (PDF)

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double‐blind placebo‐controlled trial of high‐ vs. low‐dose atorvastatin 1

Diabetic medicine, 2011-01, Vol.28 (1), p.100-108

2011

Volltextzugriff (PDF)

Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins

Atherosclerosis, 1992, Vol.92 (1), p.49-57

1992

Volltextzugriff (PDF)

Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis

Nephrology, dialysis, transplantation, 1993, Vol.8 (1), p.71-74

1993

Volltextzugriff (PDF)

Methods for the prediction of coronary heart disease risk

Heart (British Cardiac Society), 2001-05, Vol.85 (5), p.489-490

2001

Volltextzugriff (PDF)

Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy

Clinical endocrinology (Oxford), 2004-12, Vol.61 (6), p.760-767

2004

Volltextzugriff (PDF)

Coronary risk assessment methods and cholesterol lowering

The Lancet (British edition), 1999-03, Vol.353 (9158), p.1096-1097

1999

Volltextzugriff (PDF)

Indications for cholesterol-lowering medication: comparison of risk-assessment methods

The Lancet (British edition), 1999-01, Vol.23, p.278-281

1999

Volltextzugriff (PDF)

Coronary risk assessment methods and cholesterol lowering

The Lancet (British edition), 1999-03, Vol.353 (9158), p.1095-1095

1999

Volltextzugriff (PDF)

Effects of a new fish oil concentrates on plasma lipids and lipoproteins in patients with hypertriglyceridaemia

European journal of clinical nutrition, 1994, Vol.48 (12), p.859-865

1994

Volltextzugriff (PDF)

Increased transfer of cholesteryl ester (CE) to low density lipoproteins (VLDL & LDL) associated with coronary artery disease (CAD)

Atherosclerosis, 1993-01, Vol.98 (1), p.116-116

1993

Volltextzugriff (PDF)

P410 Patient satisfaction after transition to adult CF clinic

Journal of cystic fibrosis, 2024-06, Vol.23, p.S193-S194

2024

Volltextzugriff (PDF)

P305 Pancreatic function is not a risk factor for cystic fibrosis-related bone disease

Journal of cystic fibrosis, 2024-06, Vol.23, p.S162-S162

2024

Volltextzugriff (PDF)

P091 Dual inhaled antibiotics for treatment of pulmonary exacerbations in cystic fibrosis – a real life pilot study

Journal of cystic fibrosis, 2024-06, Vol.23, p.S95-S95

2024

Volltextzugriff (PDF)

P222 Airway Achromobacter xylosoxidans and disease severity in cystic fibrosis

Journal of cystic fibrosis, 2024-06, Vol.23, p.S137-S137

2024

Volltextzugriff (PDF)

P066 Treatment effects of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for 3849 + 10 kbC->T

Journal of cystic fibrosis, 2024-06, Vol.23, p.S87-S87

2024

Volltextzugriff (PDF)

Microbial contamination of nebulizers in the home treatment of cystic fibrosis

Child : care, health & development, 2007-07, Vol.33 (4), p.491-495

2007

Volltextzugriff (PDF)

P121 Vaccine coverage in people with cystic fibrosis

Journal of cystic fibrosis, 2023-06, Vol.22, p.S101-S101

2023

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(58)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Humans
(17)
Life Sciences & Biomedicine
(16)
Biological And Medical Sciences
(12)
Male
(12)
Medical Sciences
(11)
Middle Aged
(10)
Adult
(8)
Female
(8)
Cholesterol
(6)
Lipoproteins
(6)
Pediatrics
(6)
Aged
(4)
Double-Blind Method
(4)
Fundamental And Applied Biological Sciences. Psychology
(4)
Lipoproteins - Blood
(4)
Pulmonary/respiratory
(4)
Reviews
(4)
Triglycerides
(4)
United Kingdom
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Working conditions and common mental disorders in physicians in Brazil

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin

Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia

Indications for cholesterol-lowering medication: comparison of risk-assessment methods

Methods for the prediction of coronary heart disease risk

Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia

Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double‐blind placebo‐controlled trial of high‐ vs. low‐dose atorvastatin1

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double‐blind placebo‐controlled trial of high‐ vs. low‐dose atorvastatin 1

Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins

Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis

Methods for the prediction of coronary heart disease risk

Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy

Coronary risk assessment methods and cholesterol lowering

Indications for cholesterol-lowering medication: comparison of risk-assessment methods

Coronary risk assessment methods and cholesterol lowering

Effects of a new fish oil concentrates on plasma lipids and lipoproteins in patients with hypertriglyceridaemia

Increased transfer of cholesteryl ester (CE) to low density lipoproteins (VLDL & LDL) associated with coronary artery disease (CAD)

P410 Patient satisfaction after transition to adult CF clinic

P305 Pancreatic function is not a risk factor for cystic fibrosis-related bone disease

P091 Dual inhaled antibiotics for treatment of pulmonary exacerbations in cystic fibrosis – a real life pilot study

P222 Airway Achromobacter xylosoxidans and disease severity in cystic fibrosis

P066 Treatment effects of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for 3849 + 10 kbC->T

Microbial contamination of nebulizers in the home treatment of cystic fibrosis

P121 Vaccine coverage in people with cystic fibrosis

Suchergebnisse filtern